Considering that FBXO9 expression is reduced in AML patients and that this reduction correlates with a negative prognosis, we generated a cKO mouse to provide a model for studying the role of FBXO9 in the tumor-initiating population, and in the development and progression of AML. The gene discussed is FBXO9; the disease is neoplasm.